Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
RNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Self-citationRNA-Binding Proteins in Cancer: Old Players and New Actors
Pereira, B., Billaud, M., & Almeida, R. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.05.003 · Cited by 773
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
“recognition by eukaryotic initiation factor 4F (eIF4F) and the assembly of the preinitiation complex (PIC), which consists of the ternary complex, the 40S ribosomal subunit, eIF1, eIF1A, eIF3 and eIF5.(21) eIF4F consists of eIF4A, eIF4E and eIF4G, which facilitates PIC recruitment by eIF4E–cap and eIF4G–eIF3 interacti…”
BackgroundmTOR as a central regulator of lifespan and aging
Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F., Topisirovic, I., & Hulea, L. (2019) · F1000Research · doi:10.12688/f1000research.17196.1 · Cited by 440
Self-citationThe mammalian ribo-interactome reveals ribosome functional diversity and heterogeneity
Simsek, D., Tiu, G. C., Flynn, R. A., Byeon, G. W., Leppek, K., Xu, A. F., Chang, H. Y., & Barna, M. (2017) · Cell · doi:10.1016/j.cell.2017.05.022 · Cited by 439
“As direct inhibitors of protein synthesis hold promise in the treatment of cancers (Bhat et al., 2015), it will be interesting to determine whether PKM mutations found in human cancers may sensitize these cells to specific translational inhibitors.”
Non-AUG translation: a new start for protein synthesis in eukaryotes
Kearse, M. G., & Wilusz, J. E. (2017) · Genes & Development · doi:10.1101/gad.305250.117 · Cited by 387
Loftus, R. M., Assmann, N., Kedia-Mehta, N., O’Brien, K. L., Garcia, A., Gillespie, C., Hukelmann, J. L., Oefner, P. J., Lamond, A. I., Gardiner, C. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04719-2 · Cited by 381
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
RNA-binding proteins in tumor progression
Qin, H., Ni, H., Liu, Y., Yuan, Y., Xi, T., Li, X., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00927-w · Cited by 375
mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1
Morita, M., Prudent, J., Basu, K., Goyon, V., Katsumura, S., Hulea, L., Pearl, D., Siddiqui, N., Strack, S., McGuirk, S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.013 · Cited by 373
Self-citationDeregulation of ribosomal protein expression and translation promotes breast cancer metastasis
Ebright, R. Y., Lee, S., Wittner, B. S., Niederhoffer, K. L., Nicholson, B. T., Bardia, A., Truesdell, S., Wiley, D. F., Wesley, B., Li, S., et al. (2020) · Science · doi:10.1126/science.aay0939 · Cited by 365
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
“Unphosphorylated 4E-BP1 binds to and thereby inhibits eukaryotic translation initiation factor 4E (eIF4E) (Bhat et al. 2015).”
BackgroundInfluentialMETTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis
Su, R., Dong, L., Li, Y., Gao, M., He, P. C., Liu, W., Wei, J., Zhao, Z., Gao, L., Han, L., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00835-2 · Cited by 335
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirovic, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 324
“such as cancer (34, 206), neurological disorders (313, 314), and aging (315, 316).”
BackgroundErratum: New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.30 · Cited by 303
Translational Control in Cancer
Robichaud, N., Sonenberg, N., Ruggero, D., & Schneider, R. J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032896 · Cited by 302
“This can be achieved through a variety of complex molecular alterations that increase selective translation of poorly translated mRNAs, including increased expression or availability of certain translation initiation factors, and increased activity of signaling pathways regulating them (reviewed in Silvera et al. 2010…”
BackgroundSelf-citationRibosome Profiling: Global Views of Translation
Ingolia, N. T., Hussmann, J. A., & Weissman, J. S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032698 · Cited by 286
“As mTOR activity drives cell growth downstream fromwell-known oncogenic signaling pathways, there is great interest in developing active-site mTOR inhibitors as clinically useful anticancer therapies (Bhat et al. 2015).”
BackgroundDrug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
“The significantly decreased microRNA (miRNA)-125b in MCF-7 causes DOX-resistant [22].”
BackgroundInfluentialThe Organizing Principles of Eukaryotic Ribosome Recruitment
Pelletier, J., & Sonenberg, N. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111042 · Cited by 271
Self-citationTranslation deregulation in human disease
Tahmasebi, S., Khoutorsky, A., Mathews, M. B., & Sonenberg, N. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0034-x · Cited by 255
Self-citationTranslational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Self-citationPeptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Hoppenz, P., Els-Heindl, S., & Beck-Sickinger, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00571 · Cited by 242
“For example, the dysregulation of translational regulators (Bhat et al., 2015), altered epigenetic regulation mechanisms (Pfister and Ashworth, 2017), the overproduction of enzymes (DeBerardinis and Chandel, 2016) or changes in the cellular microenvironment such as a lower pH (Kato et al.”
BackgroundProteome complexity and the forces that drive proteome imbalance
Harper, J. W., & Bennett, E. J. (2016) · Nature · doi:10.1038/nature19947 · Cited by 238
The molecular basis of translation initiation and its regulation in eukaryotes
Brito Querido, J., Díaz-López, I., & Ramakrishnan, V. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00624-9 · Cited by 233
“It has long been known that the activity of eIF4F is upregulated in cancer cells, which have increased translation 113,114,220 , whereas it is downregulated during viral infection as a strategy to shut down host–gene translation.”
mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
de la Cruz López, K. G., Toledo Guzmán, M. E., Sánchez, E. O., & García Carrancá, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01373 · Cited by 223
“It is well-established that deregulation of mRNA translation is a prominent characteristic of cancer cells (94).”
BackgroundSiddiqui, N., & Sonenberg, N. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150126 · Cited by 220
Self-citationDynamics of ribosome scanning and recycling revealed by translation complex profiling
Archer, S. K., Shirokikh, N. E., Beilharz, T. H., & Preiss, T. (2016) · Nature · doi:10.1038/nature18647 · Cited by 220
Regulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S. A., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 216
“NVPBGT226 has also been shown to exert cytotoxic effects against other cancer cell types such as ALK-positive anaplastic large cell lymphoma [615] and hepatocellular carcinoma [616] and has entered Phase I/II clinical trials for breast cancer [617].”
BackgroundMETTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis
Liu, S., Hausmann, S., Carlson, S. M., Fuentes, M. E., Francis, J. W., Pillai, R., Lofgren, S. M., Hulea, L., Tandoc, K., Lu, J., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.038 · Cited by 210
Self-citationYue, M., Jiang, J., Gao, P., Liu, H., & Qing, G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.002 · Cited by 202
Queuosine‐modified tRNAs confer nutritional control of protein translation
Tuorto, F., Legrand, C., Cirzi, C., Federico, G., Liebers, R., Müller, M., Ehrenhofer‐Murray, A. E., Dittmar, G., Gröne, H., & Lyko, F. (2018) · The EMBO Journal · doi:10.15252/embj.201899777 · Cited by 201
“Ingenuity pathway analysis revealed a strong enrichment for genes involved in eIF2 signaling (Fig 4B) a critical point of stress-induced regulation of translation in eukaryotic cells (Bhat et al , 2015).”
Goetzman, E. S., & Prochownik, E. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00129 · Cited by 199
“Protein synthesis rates and ribosomal protein content are known to be rate-limiting factors in the growth of many cancers (108, 268).”
BackgroundCancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer
Mohibi, S., Chen, X., & Zhang, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.001 · Cited by 199
“Several small molecules have been developed to target this protein family by affecting the RNA binding and helicase activity or by disrupting specific protein-protein interactions (Bhat et al., 2015; Cai et al., 2017).”
BackgroundLARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs
Hong, S., Freeberg, M. A., Han, T., Kamath, A., Yao, Y., Fukuda, T., Suzuki, T., Kim, J. K., & Inoki, K. (2017) · eLife · doi:10.7554/elife.25237 · Cited by 197
“Mechanistic target of rapamycin complex 1 (mTORC1) functions as a positive regulator of translation initiation and protein synthesis to promote cell growth and proliferation (Bhat et al., 2015; Dibble and Manning, 2013).”
BackgroundAnalysis of cancer-related lncRNAs using gene ontology and KEGG pathways
Chen, L., Zhang, Y.-H., Lu, G., Huang, T., & Cai, Y.-D. (2017) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.02.001 · Cited by 186
Protein translation: biological processes and therapeutic strategies for human diseases
Jia, X., He, X., Huang, C., Li, J., Dong, Z., & Liu, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01749-9 · Cited by 188
“41 While mechanisms underlying noncanonical translation initiation vary in terms categories involving different eIFs, they share common features such as cap recognition and ribosome scanning manner as well as other conditions.”
BackgroundHan, H., Yang, C., Ma, J., Zhang, S., Zheng, S., Ling, R., Sun, K., Guo, S., Huang, B., Liang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29125-7 · Cited by 181
RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer
Li, W., Deng, X., & Chen, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.025 · Cited by 175
Reich, S. H., Sprengeler, P. A., Chiang, G. G., Appleman, J. R., Chen, J., Clarine, J., Eam, B., Ernst, J. T., Han, Q., Goel, V. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01795 · Cited by 175
Translation is actively regulated during the differentiation of CD8+ effector T cells
Araki, K., Morita, M., Bederman, A. G., Konieczny, B. T., Kissick, H. T., Sonenberg, N., & Ahmed, R. (2017) · Nature Immunology · doi:10.1038/ni.3795 · Cited by 175
“The translational regulation of gene expression is involved in many cellular events, and its dysregulation can result in clinical manifestations, including cancer and mental disorders 9, 10, 11 .”
BackgroundSelf-citationRNA G-quadruplexes and their potential regulatory roles in translation
Song, J., Perreault, J., Topisirović, I., & Richard, S. (2016) · Translation · doi:10.1080/21690731.2016.1244031 · Cited by 175
“As a key factor in cap-dependent translation initiation, eIF4A plays a role in scanning the 50-UTR of the mRNAs for start codons.(73) Notably, eIF4A inhibitors including Figure 2.”
BackgroundVrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 176
Lessard, F., Igelmann, S., Trahan, C., Huot, G., Saint-Germain, E., Mignacca, L., Del Toro, N., Lopes-Paciencia, S., Le Calvé, B., Montero, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0127-y · Cited by 174
How Ribosomes Translate Cancer
Sulima, S. O., Hofman, I. J. F., De Keersmaecker, K., & Dinman, J. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0550 · Cited by 173
“Additionally, patients with DBA have a 287-fold higher risk of developing MDS, which in turn predisposes to AML (49).”
BackgroundInfluentialMerrick, W. C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.675280 · Cited by 172
RNA-binding proteins and cancer metastasis
Wang, S., Sun, Z., Lei, Z., & Zhang, H.-T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.018 · Cited by 169
Aptamers: Uptake mechanisms and intracellular applications
Yoon, S., & Rossi, J. J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.003 · Cited by 169
“The translational dysregulation for the increased cellular proliferation and pro-oncogenic mRNAs is a hallmark of many cancers [94, 95].”
BackgroundHow the evolution of multicellularity set the stage for cancer
Trigos, A., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.398 · Cited by 165
“…topology that results in a consistent convergence to the upregulation and increased phosphorylation of eIF4E directed by a broad set of oncogenes (Bhat et al, 2015), reinforcing the importance of mediators of communication between genes of unicellular and multicellular origin in cancer aetiology.”
BackgroundDrugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play”
Newman, D., & Cragg, G. (2016) · Planta Medica · doi:10.1055/s-0042-101353 · Cited by 159
“For more information on these pathways, the two recent reviews from the Pelletier group at McGill University should be consulted [109,110].”
Spatial Organization of Single mRNPs at Different Stages of the Gene Expression Pathway
Adivarahan, S., Livingston, N. M., Nicholson, B. L., Rahman, S., Wu, B., Rissland, O. S., & Zenklusen, D. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.010 · Cited by 157
The regulation of protein translation and its implications for cancer
Song, P., Yang, F., Jin, H., & Wang, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00444-9 · Cited by 157
“After the translation initiation complex is assembled, the 40S ribosomal subunit binds to other initiation factors, including eIF5 and the ternary complex (eIF2-GTP-MettRNAi) to form a 43S ribosome, thus enabling the progression into the extension stage.(9,10) The initiation complex of cap-dependent translation scans…”
MethodCross-talk between protein synthesis, energy metabolism and autophagy in cancer
Lindqvist, L., Tandoc, K. V., Topisirović, I., & Furic, L. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.11.003 · Cited by 154
“Current Opinion in Genetics & Development 2018, 48:104–111 translation apparatus [1].”
InfluentialTranslation initiation by cap‐dependent ribosome recruitment: Recent insights and open questions
Shirokikh, N. E., & Preiss, T. (2018) · WIREs RNA · doi:10.1002/wrna.1473 · Cited by 143
“For example, dysregulation of most of the eukaryote-specific eIFs is implicated in the onset of malignancies and is regarded as one of the drivers of oncogenesis (Bhat et al., 2015; Hershey, 2010).”
BackgroundErnst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150
Nanoarchitecture Frameworks for Electrochemical miRNA Detection
Masud, M. K., Umer, M., Hossain, M. S. A., Yamauchi, Y., Nguyen, N., & Shiddiky, M. J. A. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.012 · Cited by 149
Tabet, R., Schaeffer, L., Freyermuth, F., Jambeau, M., Workman, M., Lee, C.-Z., Lin, C.-C., Jiang, J., Jansen-West, K., Abou-Hamdan, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02643-5 · Cited by 141
Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression
Khattar, E., Kumar, P., Liu, C. Y., Akıncılar, S. C., Raju, A., Lakshmanan, M., Maury, J. J. P., Yu, Q., Li, S., Tan, E. Y., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86042 · Cited by 145
Widespread Translational Remodeling during Human Neuronal Differentiation
Blair, J. D., Hockemeyer, D., Doudna, J. A., Bateup, H. S., & Floor, S. N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.095 · Cited by 135
Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer
Chu, J., Cargnello, M., Topisirović, I., & Pelletier, J. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.06.005 · Cited by 142
Self-citationThe ribosome, (slow) beating heart of cancer (stem) cell
Bastide, A., & David, A. (2018) · Oncogenesis · doi:10.1038/s41389-018-0044-8 · Cited by 140
Lintner, N. G., McClure, K. F., Petersen, D., Londregan, A. T., Piotrowski, D. W., Wei, L., Xiao, J., Bolt, M., Loria, P. M., Maguire, B., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001882 · Cited by 128
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 125
eIF3: a factor for human health and disease
Gomes‐Duarte, A., Lacerda, R., Menezes, J., & Romão, L. (2017) · RNA Biology · doi:10.1080/15476286.2017.1391437 · Cited by 138
“ation factors are frequently gained or lost in human tumors and thus are aberrantly expressed during cancer progression.(57) Among these genes, there are those encoding the eIF3 subunits.”
BackgroundAkt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells
Gocher, A. M., Azabdaftari, G., Euscher, L. M., Dai, S., Karacosta, L. G., Franke, T. F., & Edelman, A. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.778464 · Cited by 134
“Akt regulates protein translation by direct phosphorylation of PRAS40 at Thr-246, which releases the inhibition of raptor, resulting in mTORC1 phosphorylation of S6K and 4E-BP1 (45).”
The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation
Sun, L.-Y., Wang, W., Han, C., Huang, W., Sun, Y., Fang, K., Zeng, Z., Yang, Q., Pan, Q., Chen, T., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.033 · Cited by 134
Dynamics of IRES-mediated translation
Johnson, A. G., Grosely, R., Petrov, A. N., & Puglisi, J. D. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0177 · Cited by 133
Westergard, T., McAvoy, K., Russell, K., Wen, X., Pang, Y., Morris, B., Pasinelli, P., Trotti, D., & Haeusler, A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809423 · Cited by 126
“…the ISR or translation-related pathways that are currently in use or have been used in clinical trials for neurodegenerative diseases or cancer (Bhat et al, 2015) Specifically, trazodone and dibenzoylmethane (1,3 DBM), which recover the eif2a ternary complex and prevent increased ATF4…”
MethodThe Growing Toolbox for Protein Synthesis Studies
Iwasaki, S., & Ingolia, N. T. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.05.004 · Cited by 123
“Indeed, retuning of the aberrant translation status by translation inhibitors is an attractive strategy for tumor treatment [2].”
BackgroundA Conserved Mito-Cytosolic Translational Balance Links Two Longevity Pathways
Molenaars, M., Janssens, G. E., Williams, E. G., Jongejan, A., Lan, J., Rabot, S., Joly, F., Moerland, P. D., Schomakers, B. V., Lezzerini, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.011 · Cited by 124
“With cytosolic translation already established as a target for cancer therapy (Bhat et al., 2015; Faller et al., 2015; Pelletier et al., 2018), our work points to the possibility that this could be achieved through the cellular mechanisms in place to achieve mito-cytosolic translation balance.”
BackgroundTranslational control of breast cancer plasticity
Jewer, M., Lee, L. J., Leibovitch, M., Zhang, G., Liu, J., Findlay, S. D., Vincent, K. M., Tandoc, K. V., Dieters‐Castator, D. Z., Quail, D. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16352-z · Cited by 126
Translation acrobatics: how cancer cells exploit alternate modes of translational initiation
Sriram, A., Bohlen, J., & Teleman, A. A. (2018) · EMBO reports · doi:10.15252/embr.201845947 · Cited by 110
“In summary, these discoveries pave the way for the discovery of novel anti-cancer drugs that target the components of the cap-dependent translation machinery [205 – 209].”
Du, T., Zhu, L., Levine, K. M., Tasdemir, N., Lee, A. V., Vignali, D. A. A., Houten, B. V., Tseng, G. C., & Oesterreich, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25357-0 · Cited by 121
Wanted DEAD/H or Alive: Helicases Winding Up in Cancers
Cai, W., Chen, Z. X., Rane, G., Singh, S. S., Choo, Z., Wang, C., Yuan, Y., Tan, T. Z., Arfuso, F., Yap, C. T., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw278 · Cited by 119
“The involvement of eIF4A isoforms makes them attractive therapeutic targets (52,53) and good prognostic biomarkers to predict survival outcome for these gynecological cancers (44).”
BackgroundIslam, M. N., Masud, M. K., Haque, M. H., Hossain, M. S. A., Yamauchi, Y., Nguyen, N., & Shiddiky, M. J. A. (2017) · Small Methods · doi:10.1002/smtd.201700131 · Cited by 119
mTORC1 and CK2 coordinate ternary and eIF4F complex assembly
Gandin, V., Masvidal, L., Cargnello, M., Gyenis, L., McLaughlan, S., Cai, Y., Tenkerian, C., Morita, M., Balanathan, P., Jean-Jean, O., et al. (2016) · Nature Communications · doi:10.1038/ncomms11127 · Cited by 103
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 118
“It is not clear how thesemutationsmight promote cancer, but the dysregulation of mRNA translation is a frequent feature of neoplasia (Bhat et al. 2015).”
BackgroundRobichaud, N., Hsu, B. E., Istomine, R., Alvarez, F., Blagih, J., Ma, E. H., Morales, S. V., Dai, D. L., Li, G., Souleimanova, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717439115 · Cited by 112
“overexpressed in a wide range of cancers, including breast, prostate, head and neck, leukemia, and lymphoma (1, 2).”
BackgroundSelf-citationTranslational control of aberrant stress responses as a hallmark of cancer
El-Naggar, A. M., & Sorensen, P. H. B. (2018) · The Journal of Pathology · doi:10.1002/path.5030 · Cited by 111
“PI3K–AKT and Ras–ERK pathways are stimulated by exogenous growth factors and hormones [41,47], while mTOR requires specific amino acids (Leu and Arg) for activation [48], reviewed in ref 49.”
BackgroundInfluentialCancer Plasticity: The Role of mRNA Translation
Lee, L. J., Papadopoli, D. J., Jewer, M., Rincon, S. V. D., Topisirović, I., Lawrence, M. G., & Postovit, L.-M. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.005 · Cited by 110
“Accordingly, stem cells and differentiated adult cells, as well as nonmalignant and neoplastic cells, have distinct translational programs [5,21,22].”
BackgroundInfluentialTuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK–eIF4E Axis
Bramham, C. R., Jensen, K. B., & Proud, C. G. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.07.008 · Cited by 110
RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection
Liu, G., Du, W., Sang, X., Tong, Q., Wang, Y., Chen, G., Yuan, Y., Jiang, L., Cheng, W., Liu, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29135-5 · Cited by 108
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
“Clin Cancer Res; 23(1) January 1, 2017 Clinical Cancer Research 22”
BackgroundKapadia, B. B., Nanaji, N. M., Bhalla, K., Bhandary, B., Lapidus, R. G., Beheshti, A., Evens, A. M., & Gartenhaus, R. B. (2018) · Nature Communications · doi:10.1038/s41467-018-03028-y · Cited by 105
Bohlen, J., Harbrecht, L., Blanco, S., von Hohenberg, K. C., Fenzl, K., Krämer, G., Bukau, B., & Teleman, A. A. (2020) · Nature Communications · doi:10.1038/s41467-020-18452-2 · Cited by 105
Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers
Challa, S., Khulpateea, B. R., Nandu, T. S., Camacho, C. V., Ryu, K. W., Chen, H., Peng, Y. S., Lea, J. S., & Kraus, W. L. (2021) · Cell · doi:10.1016/j.cell.2021.07.005 · Cited by 105
mTOR-dependent translation amplifies microglia priming in aging mice
Keane, L., Antignano, I., Riechers, S.-P., Zollinger, R., Dumas, A. A., Offermann, N., Bernis, M. E., Russ, J., Graelmann, F., McCormick, P. N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci132727 · Cited by 86
“In particular, mRNAs involved in proliferation, cell growth, and immune responses are more sensitive to eIF4E activity (34–38), for Microglia maintain homeostasis in the brain.”
Kim, D. W., Wu, N., Kim, Y., Cheng, P. F., Basom, R., Kim, D., Dunn, C. T., Lee, A. Y., Kim, K., Lee, C. S., et al. (2016) · Genes & Development · doi:10.1101/gad.279307.116 · Cited by 103
“The protein translation machinery can be targeted at multiple levels beyond RNA Pol I inhibition, such as through inhibition of mTOR signaling or various EIF4F complex components that control translation initiation (Bhat et al. 2015).”
BackgroundMYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L.-G. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 90
HSP90: Enabler of Cancer Adaptation
Jaeger, A. M., & Whitesell, L. J. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055533 · Cited by 99
“…extracellular processes, including damage to macromolecules such as proteins, lipids, and nucleic acids; restricted access to nutrients; increased demand for biosynthetic processes; exposure to toxins; and attack from immune cells (Bhat et al. 2015, Pavlova & Thompson 2016, Santagata et al. 2013).”
BackgroundThe roles and mechanisms of YTH domain-containing proteins in cancer development and progression.
Liu, S., Li, G., Li, Q., Zhang, Q., Zhuo, L., Chen, X., Zhai, B., Sui, X., Chen, K., & Xie, T. (2020) · PubMed · Cited by 99
SMN-primed ribosomes modulate the translation of transcripts related to spinal muscular atrophy
Lauria, F., Bernabò, P., Tebaldi, T., Groen, E. J. N., Perenthaler, E., Maniscalco, F., Rossi, A., Donzel, D., Clamer, M., Marchioretto, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-00577-7 · Cited by 98
The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
Dong, H.-J., Wang, Z., Meng, W., Li, C.-C., Hu, Y., Zhou, L., & Wang, X.-J. (2018) · Viruses · doi:10.3390/v10110601 · Cited by 99
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo
Tödt, D., Moeller, N., Praditya, D., Kinast, V., Friesland, M., Engelmann, M., Verhoye, L., Sayed, I. M., Behrendt, P., Thi, V. L. D., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.010 · Cited by 97
“Noteworthy, clinical efforts are underway to target specific components of the translation apparatus or unique mRNA translation elements in cancer therapeutics (Silvera et al., 2010; Bhat et al., 2015).”
BackgroundChu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A., & Pelletier, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.005 · Cited by 95
“Strategies aimed at inhibiting eIF4F include blocking eIF4E:eIF4G and eIF4E-cap interaction, interfering with eIF4A1/2 activity, and suppressing eIF4E expression with antisense oligonucleotides (ASOs) (Bhat et al., 2015).”
BackgroundSelf-citationHulea, L., Gravel, S.-P., Morita, M., Cargnello, M., Uchenunu, O., Im, Y. K., Lehuédé, C., Ma, E. H., Leibovitch, M., McLaughlan, S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.001 · Cited by 91
“This is in part mediated by the effects of mTORC1 on 4E-BPs and, consequently, on the eIF4F complex assembly (Bhat et al., 2015).”
BackgroundMethodInfluentialSelf-citationRole of network-mediated stochasticity in mammalian drug resistance
Farquhar, K. S., Charlebois, D. A., Szenk, M., Cohen, J., Nevozhay, D., & Balázsi, G. (2019) · Nature Communications · doi:10.1038/s41467-019-10330-w · Cited by 92
Malik, N., Yan, H., Moshkovich, N., Palangat, M., Yang, H. H., Sanchez, V. C., Cai, Z., Peat, T. J., Jiang, S., Liu, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10102-6 · Cited by 95
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Since there are a few reviews of similar topics from earlier years, we will be focusing on the advantages of the last 5 years (Stellrecht and Chen, 2011; Villicaña et al., 2014; Bhat et al., 2015).”
Background
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.